Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Recombinant Interleukin-6 - Sonnet Biotherapeutics Holdings

Next Previous
X
Search
Drug Profile

Recombinant Interleukin-6 - Sonnet Biotherapeutics Holdings

Alternative Names: atexakin alfa; r-IL-6; recombinant IL-6; SON 080; SON-081

Latest Information Update: 14 Oct 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Weizmann Institute of Science
  • Developer RELIEF THERAPEUTICS Holding; Sonnet BioTherapeutics Holdings, Inc; Xequel Bio
  • Class Antineoplastics; Interleukins
  • Mechanism of Action Interleukin replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Peripheral nerve injuries
  • Phase I Diabetic neuropathies

Most Recent Events

  • 09 Oct 2024 Recombinant Interleukin-6 licensed to Alkem Laboratories in India
  • 24 Jul 2024 Adverse events data from a phase Ib/IIa trial in Peripheral nerve injuries released by Sonnet BioTherapeutics
  • 12 Apr 2024 Sonnet BioTherapeutics terminates a phase I/II trial in Peripheral nerve injuries in Australia (SC), due to lack of enrolment (NCT05435742)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top